A Multicenter, Randomized, Double-Blind Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone For The Treatment of Antiretroviral-Experienced Non CCR5-Tropic HIV-1 Infected Subject
- Conditions
- HIV-1 treatment in combination with other agentsMedDRA version: 6.1Level: PTClassification code 10020161
- Registration Number
- EUCTR2004-001779-20-IT
- Lead Sponsor
- Pfizer LTD, Pfizer Global RD-Sandwich Laboratories-I.P.C. 582
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 192
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method